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Cyclic RGD peptides ameliorate ischemic acute renal failure in rats.
Renal tubular obstruction is an important contributor to the pathophysi-
ology of acute renal failure. Based on the previous findings of the role
played by arginine-glycine-aspartic acid (RGD) recognizing integrins in
tubular obstruction, this study examined the effect of RGD peptides on
the course of ischemic acute renal failure in rats. For in vivo studies,
animals were subjected to 45 minutes of unilateral renal ischemia with
contralateral nephrectomy, and cyclic ROD peptides or a linear biotiny-
lated RGD peptide were injected systemically after the release of renal
artery clamp. In vitro studies compared the potency of the peptides in
inhibiting BS-C-1 cell-matrix and cell-cell adhesion. Two novel cyclic
RGD peptides utilized in these studies showed different inhibitory potency
in preventing cell-matrix adhesion: cyclic RGDDFV was a highly potent in
vitro inhibitor of BS-C-1 cell-matrix adhesion, whereas cyclic RGDDFLG
was less potent. In cell-cell adhesion assays, however, both peptides were
equipotent. Despite the differences in inhibiting cell-matrix adhesion, a
single systemic administration of either peptide improved creatinine
clearance postoperatively and accelerated recovery of renal function with
a rank order: cyclic RGDDFV  RGDDFLG ° RDADFV (inactive
control). These findings represent the first in vivo demonstration of the
effectiveness of cyclic RGD peptides in ameliorating ischemic acute renal
failure, and suggest that in this setting RGD peptides predominantly
inhibit cell-cell adhesion, whereas inhibition of cell-matrix adhesion is of
lesser significance.
mediate cell-cell adhesion via an arginine-glycine-aspartic acid-
(RGD) inhibitable mechanism [7]. The subsequent in vivo studies
have provided evidence that infusion of a synthetic ROD peptide
into the renal artery during the reperfusion period abolished the
characteristic elevation in the proximal tubular pressure which
served as an index of tubular obstruction [8]. Although the
concentration of the peptide used in these experiments was low
(approximate calculated intratubular concentration was ca 10
,xM), the remote possibility of the peptide-induced desquamation
of tubular epithelia, thus resulting in an artifactual reduction in
proximal tubular pressure due to the increased backleak, re-
mained to be ruled out.
In the present study, we report the results of experiments on
systemic administration of two highly potent cyclic RGD peptides
[9] infused after the release of renal artery clamp in the ischemic
model of acute renal failure. In these experiments, a single
administration of these peptides resulted in the accelerated
improvement of renal function following the induction of isch-
emia.
Methods
Cell culture, cell-matrix and cell-cell attachment assays
Tubular obstruction is an important pathophysiological event
leading to oliguria which persists long after the inception of acute
renal failure [1—41. It has been postulated that necrotic cells and
cell debris are the major constituents of casts obstructing the
tubular lumen. More recent studies, however, have provided
conclusive evidence that viable epithelial cells are excreted in the
urine of patients and experimental animals with acute renal
failure [5, 6], thus raising the alternative possibility that exfoliation
of tubular epithelial cells is a cause of tubular obstruction. Using
cultured renal tubular epithelial cells and rats with ischemic acute
renal failure, we have previously demonstrated that the detach-
ment of viable tubular epithelial cells is caused, at least in part, by
the reorientation of integrin receptors from a predominantly
basolateral location to the apical membrane, where they can
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Renal epithelial cell line BS-C-1, derived from African green
monkey kidney, were routinely cultured in minimal essential
medium (MEM), supplemented with 10% fetal bovine serum, as
previously detailed [7].
Cell-matrix attachment assay. The cell-matrix attachment assay
was performed as previously described [10]. Briefly, 96-well
microtiter plates were coated with matrix proteins dissolved in
phosphate-buffered saline (PBS) at 4°C; 50 p.1 were added to each
well. Proteins were used at the following concentrations (in
p.g/ml): 40 laminin (GIBCO BRL, Gaithersburg, Maryland,
USA), 5 PepTite 2000 (GIBCO BRL), 5 fibronectin (New York
Blood Center, New York, NY, USA), 40 type IV collagen
(GIBCO BRL), 40 human serum albumin, 2.5 ProNectin F
(Protein Polymer Technologies, San Diego, California, USA).
After overnight coating, the wells were washed three times with
PBS, and any remaining uncoated plastic surface was blocked by
treatment with 50 jxl of 20 mg/ml human serum albumin in PBS at
room temperature for 120 minutes. Before use in the assay, the
wells were again washed three times with PBS. BS-C-1 cells were
dispersed with 0.05% trypsin-0.02% EDTA. After inactivation of
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Fig. 1. Plots of the refined confonnaaons of
the cyclic peptides. Cyclic RGDDFV peptide
(left), cyclic RGDDFLG peptide (middle),
cyclic RDADFV peptide (right). Only heavy
atoms and polar hydrogens are shown.
Oxygen atoms are depicted as filled circles,
nitrogens as stippled circles and carbons are
shown as plain circles. Hydrogen bonds are
indicated as dashed lines.
trypsin with soybean trypsin inhibitor dissolved in MEM, the cells
were washed twice in MEM with 0.1% albumin, and then resus-
pended in the same medium at a concentration of 180,000
cells/ml. Cell adhesion to matrix proteins was measured by adding
100 1.d of cell suspension to coated wells of the microtiter plate.
Before adding cells, 25 LM cyclic RGDDFLG or cyclic RGDDFV
peptide was introduced into the cell suspension. In control
studies, cells was treated with either 25 LM inactive peptide, cyclic
RDADFV, or with PBS. After incubation at 37°C for 60 minutes,
unattached cells were removed by gentle washing with PBS.
Attached cells were fixed with 1% glutaraldehyde (20 mm at room
temperature). Plates were then washed four times with distilled
water. The number of attached cells in each well was quantitated
using the bicinchoninic acid protein assay reagent [11] (Pierce,
Rockford Illinois, USA): 200 d of reagent were added to each
well, and the color reaction was allowed to proceed overnight at
room temperature. The absorbance at 562 nm was measured with
a microtiter plate reader (Molecular Devices Corp., Menlo Park,
California, USA). Inhibitory potencies of cyclic RGDDFLG, cyclic
RGDDFV and cyclic RDADFV peptide were examined at con-
centrations ranging from 5 to 250 jiM using laminin or fibronectin
as adhesion substrates.
Cell-cell adhesion assay. For the cell-cell adhesion assay, BS-C-1
cells were dispersed with 0.05% trypsin-0.02% EDTA, washed
twice with MEM supplemented with 10% FBS, and then resus-
pended in MEM with 10% FBS, 5% penicillin/streptomycin and
25 m HEPES, at the concentration of 106 cells/ml. Cells were
transferred into Eppendorif tubes and kept on ice. Cell suspen-
sions were utilized in two types of studies: hemocytometer count-
ing of cell conglomerates and flow cytometiy analysis of aggre-
gates. Aliquots of the cell suspension were placed in a
hemocytometer and counted, as detailed below. Cyclic RGD
peptides or vehicle were added to the cell suspensions (20 jiM of
cyclic RGDDFLG, 20 jiM of cyclic RGDDFV, 20 jiM of cyclic
RDADFV peptide, phosphate buffered saline (PBS) as a control)
and the tubes were immediately transferred for incubation in a
shaking water bath at 37°C for 30 and 60 minutes. At the
appropriate times, aliquots were placed in a hemocytometer and
100 events were counted and subdivided into the following
categories: single cells, doublets, triplets, conglomerations of 4 to
5 cells, 6 to 10 cells, and conglomerates of more than 11 cells. The
data from three separate experiments, each performed in quadru-
plicate samples, were combined for the final analysis of cell-cell
adhesion.
Fluorescence-activated cell sorting (FACS) was performed with
BS-C-1 cell suspensions prepared as detailed above. Cells were
loaded with a viable cell fluorescent indicator, calcein/acetometh-
ylester, 2 jiM for 45 minutes (Molecular Probes, Eugene, Oregon,
USA), washed with Krebs buffer and stored at 4°C until FACS
analysis. Analyses were performed with a FACStar Plus cell sorter
(Becton Dickenson, San Jose, California, USA) equipped with an
Innova 90-5 argon laser (Coherent Laser Products, Palo Alto,
California, USA) tuned to 488 nm and operated at 200 mW. The
cell ejector orifice was opened to 200 jim to permit the passage of
cellular conglomerates of up to —10 to 12 cells. Side scatter (90°)
and fluorescence intensity of calcein were collected through
488/20 and 530/30 band-pass filters (Omega Optical, Brattleboro,
Vermont, USA), respectively. Samples were analyzed at the
initiation of cell suspension, and then 30 and 60 minutes later,
while being incubated in the dark in a shaking water bath at 37°C.
In parallel experiments, cell conglomeration was promoted by the
addition of 25 jiM ProNectin after acquisition of the initial
recording (positive control) or inhibited by the addition of 50 jiM
GRGDNP (negative control). At least 10,000 events were counted
in each experiment, and the data represent four separate replica-
tive experiments. The data were acquired in list mode and
analyzed using LYSIS II software (Becton Dickenson).
Surgical procedures
All experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratoty Animals (note added in
proofl. Sprague-Dawley male rats weighing 120 to 150 g were
housed in metabolic cages for three days and allowed chow and
water ad libitum. Twenty-four hour urine was collected and blood
was drawn prior to the surgery. After an overnight fast, animals
were anesthetized with 0.27 ml/100 g body weight of a cocktail
[Ketaset (Aveco Co., Iowa, USA) 0.6 ml, Rompun (Mobay Co.,
Shawnee, Kansas, USA) 0.2 ml, normal saline 0.6 mlJ. The
animals were placed on a heated surgical table, and rectal
temperature was maintained at 37°C. A 2.5 cm anterior midline
incision was made, the right kidney was externalized, and the renal
pedicle was underpassed with two 3-0 sutures. The left kidney was
exposed, the renal artely was liberated from the renal vein and
also underpassed with a 3-0 suture. Both ends of the suture were
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passed through a 1 cm polyethylene cannula. An intravenous
bolus of heparin was given at 120 U/kg five minutes before
clamping the left renal artery. Renal ischemia was initiated by
pulling the sutures and compressing the cannula against the left
renal artery. After 45 minutes, the left renal artery was released.
The right renal artery and the right ureter were ligated and a right
nephrectomy was performed. In the ROD-treated group, 12.9 jig
of cyclic RODDFLG or 13.3 jig of cyclic RGDDFV, and in the
control group, 11.8 jig of cyclic RDADFV peptide or a vehicle
were injected intraarterially. The final concentration of these
cyclic peptides was estimated at 4 jiM, assuming the total blood
volume of a rat is about 5 ml. Penicillin 0 1 >< io U was given
intraperitonealy. The incision was closed with 3-0 sutures.
During post-operative days 1 to 3, animals were again placed in
metabolic cages with food and water ad libitum, and urine and
serum were collected for clearance studies. Blood was drawn from
the tail vein at midpoint of collection interval. Serum and urinary
creatinine (Cr) were measured by colorimetric assay (Beckman
synchron CX & kit #443340). Blood urea nitrogen (BUN) was
measured by the enzymatic conductivity rate method (Beckman
synchron CX & kit #443350). All experiments were performed in
four to seven animals.
Urinary sediments of four ROD-treated rats and three rats
from control group were examined as follows. Urine samples were
centrifuged at 500 rpm for 10 minutes, aliquots of sediment were
diluted 1:100 and examined using bright-field or fluorescence
microscopy.
In a series of experiments with a biotinylated linear ROD
peptide, the surgical procedures were similar to those described
above. Three animals received a single systemic injection of the
peptide, biotinylated GRGDSPK, at an estimated circulating
concentration of 10 jIM. Urine was collected for three hours after
injection. Voided uninary sediments were centrifuged at 500 rpm
for five minutes, washed twice with PBS and fixed with 4%
paraformaldehyde for 20 minutes. After fixation, the sediments
were washed with PBS, and stained with Rhodamine B-conju-
gated streptavidin (Molecular Probes) for 30 minutes, washed
again with PBS three times, mounted on slides, and observed
using fluorescence microscopy (Nikon Diaphot). Urine sediments
collected from three rats not injected with the biotinylated
peptide and otherwise similarly processed showed no cell-associ-
ated fluorescence staining.
Synthesis and conformational analysis of peptides
Peptide synthesis was performed on a peptide synthesizer 5P650
(Labortec), as previously described [9]. Briefly, sasrin (for cyclic
RGDDFLG and cyclic RODDFV) or o-chlorotritylchloride (for
cyclic RDADFV) resin was used with a 9-fluorenylmethoxycarbonyl
strategy in N,N-dimethylformamide. While the side chain of D was
protected as t-butyl ester, 4-methoxy-2,3,6-trimethylbenzenesulfonyl
(cyclic RGDDFLG and cyclic RGDDFV) or 2,2,5,7,8-pentamethyl-
chroman-6-sulfonyl (cyclic RDADFV) served as protecting groups
for the guanidino function of R. In the coupling reaction the pro-
tected amino acid derivatives were reacted with 4 mol/mol 1,3-
dicyclohexylcarbodiimide/1-hydroxybenzotriazole (cyclic RGDDFLG
and cyclic RODDFV) or with 3 mol/mol 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate/1-hydroxybenzotria-
zole (cyclic RoADFV) in combination with N,N-diisopropyleth-
ylamine as the basic component in 1-methyl-2-pyrrolidinone. For
deprotection of the N-terminal 9-fluorenylmethoxycarbonyl
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Fig. 2. Effect of cyclic ROD peptides on BS-C-1 cell adhesion to matrix
proteins. BS-C-1 cell attachment to fibronectin (0) and laminin (fl) was
measured in the presence of cyclic RGDDFV peptide (A), cyclic
RGDDFLG peptide (B) or with control cyclic RDADFV peptide (25 jiM;
closed symbols).
protecting groups, 20% piperidine in N,N-dimethylformamide
was used. Cleavage from the resin was performed with 1%
trifluoroacetic acid/dichloromethane (cyclic RGDDFLO and
cyclic RGDDFV) or acetic acid/2,2,2-trifluoroethanol/dichlo-
romethane (1:1:3) (cyclic RDADFV). Under these conditions the
side-chain-protecting groups are stable. The cyclization was per-
formed in N,N-dimethylformamide with 1.5 mol/mol diphe-
nylphosphorylazide over four days under high dilution at pH 8.5
to 9.0 maintained by the addition of triethylamine. Finally, the
side-chain-protecting groups were cleaved in strong acid medium,
with trifluoroacetic acid/distilled water (as a scavenger) (90:10) for
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Fig. 4. Typical patterns of urine sediment and
the appearance of the biotinylated RGD peptide
in the urine sediment. Urine samples obtained
from the cyclic RGDDFLG-treated group
contained mostly dispersed epithelial cells (A),
compared to the large cellular agglomerates
typically seen in control group (B). The data
are representative of three separate
experiments. Magnification X100. (C)
Fluorescence image of the urinary sediment
from a representative animal (N = 3) after
systemic injection of the biotinylated RGD.
(Magnification X800). The corresponding
bright-field image is shown in the inset.
(Magnification X400).
A
CB
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__________
Pre-op day 1 day 2 day 3 Pre-op day 1 day 2 day 3 Pre-op day 1 day 2 day 3
Fig. 3. Dynamics of plasma creatinine (A), BUN (B) (both in mgldl) and creatinine clearance (C) (pd/mm) in rats subjected to 45 minutes of renal ischemia.
Symbols are: (0) cRGDDFLG; (X) cRGDDFV; (•) cRDADFV; (0) control. * cRGDDFLG vs. control, P < 0.05; + cRGDDFLG vs. cRnADFV, P
< 0.05; cRGDDFV vs. control, P < 0.05; cRGDDFV vs. cRDADFV, P < 0.05. Abbreviation Pre-op is pre-operative data obtained on day 0.
cyclic RGDDFLG, with trifluoroacetic acid/p-thiocresol (95:5) for peptides was confirmed by HPLC, FABmass spectroscopy and
cyclic RGDDFV and with trifluoroacetic acid/distilled water (95:5) NMR spectroscopy. All NMR spectra were acquired on Bruker
for cyclic RDADFV. AMX 500 and AMX 600 spectrometers and processed on a
Purification of the crude peptides was achieved by high pressure Bruker X32 computer. The complete 1H and 13C assignment was
liquid chromatography (HPLC) with reverse-phase C18 3 M achieved by a combination of modern 2D-NMR experiments,
material using a gradient of distilled water/CH3CN/trifiuoroacetic both homonuclear (TOCSY, DQF-COSY) and heteronuclear
acid (95:5:0.2 to 20:80:1.0) over 15 minutes. The authenticity of (HMQC, HMQC-TOCSY, HMBCS) techniques. The amino acid
Fig. 5. Fluorescence-activated cell sorting of BS-C-1 cells self-aggregation (A), conglomeration promoted by ProNectin (B) and inhibition of spontaneous
aggregation by RGDpeptide (C). Experiments were conducted using suspended BS-C-1 cells as detailed in Methods. Consecutive cell sorting experiments
were performed at 0 (control for each group), 30 and 60 minutes. Untreated controls showed time-dependent increases in both the side scatter and the
fluorescence intensity of counted particles, consistent with their increase in size. This process was dramatically enhanced by the synthetic polymer,
ProNectin, and inhibited by the linear RGD peptide. The results were obtained on companion cells treated similarly throughout all the preparatory steps
and are representative of four similar experiments.
sequence was checked by the sequential assignment following the
main chain strategy within a 2D-NOESY. After having identified
the composition of the peptides, conformational relevant param-
eters such as temperature gradients of NH resonances (several 1D
spectra at different temperatures), homonuclear vicinal coupling
constants (P.E.COSY), heteronuclear long range couplings and
interproton distance parameter were extracted. The latter served
as experimentally derived boundaries for a computer-aided struc-
ture refinement mainly based on a molecular dynamics strategy.
All calculations were performed on Silicon Graphics 4D/25GT,
4DI7OGTB and 4D1240SX computers using the software package
INSIGHT (BIOSYM) for graphical display and model building
and the programs included in the Groningen molecular simulation
system for all energy minimization and molecular dynamic simu-
lations [12, 13]. All details concerning the NMR based structure
analysis and computational refinement procedure have been
previously described [9]. Results of the conformational analysis of
the three cyclic peptides are shown in Figure 1.
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Fig. 6. Effects of cyclic RGD or control
peptides on BS-C-1 cell-cell adhesion. Three-
dimensional plots of the proportion of cells
that underwent conglomeration as a function
of incubation time in the presence of vehicle
(Control), an inactive cyclic peptide,
RDADFV, or two active cyclic RGD
peptides. The data were combined from three
separate experiments each performed in
quadruplicate. Analysis of the data by two-
uv way ANOVA revealed the following
significant differences (P < 0.05): single40 cells—control and cRADFV vs. cRGDDFV,
control and cRoADFV vs. cRGDDFLG;
20 doublets—control vs. cRGDDFV and control
vs. cRGDDFLG; 6-10 cells— cRDADFV vs.
cRGDDFV and vs. cRGDDFLG; more than
10 cells—control and cRnADFV vs.
cRGDDFV, control and cRDADFV vs.
cRGDDFLG.
0
Biotinylation of a linear RGD peptide
A linear RGD peptide (GRGDSPK) was synthesized by the
solid-phase method of Merrifield employing standard FMOC
protocol and tertbutyl-protected amino acids. The peptide was
assembled on Wang resin using an Advanced ChemTech Model
90 peptide synthesizer. The completed peptide was cleaved from
the resin by addition of trifluoroacetic acid without prior removal
of the N-terminal FMOC protecting group to allow biotinylation
specifically at the lysine5 position (the only free amino group).
Biotinylation of the lysine5 €-amino group with a threefold molar
excess NHS-LC-Biotin II (Pierce) in DMF was completed within
eight hours at 24°C as previously described [14]. The crude
biotinylated peptide (RGD[Bt-K5]) was treated with 50% piper-
idine/DMF solution to remove the N-terminal FMOC group
followed by extraction in ice-cold ether. The crude peptide was
purified using C18 silica gel chromatography. Studies of RGD[Bt-
K5] in vitro inhibitory activity revealed its rank potency being less
than that of the cyclic RGDDFLG, but higher than that of the
inactive peptide cyclic RDADFV (data not shown).
Statistical analysis
The results are expressed as the mean SEM of the number "N"
of replicative samples. The differences between experimental
groups were analyzed using two-way analysis of variance followed
by F test. The rate of recovery of Cr and Cr within each group
was analyzed using ANOVA for continuous measures followed by
Bonferroni test. P < 0.05 was considered significant.
Results
Effects of cyclic RGD peptides on cell-matrix attachment
To examine the potency of cyclic peptides in inhibiting cell-
matrix adhesion, RGD-containing peptides and the control pep-
tide (RDADFV) were used in the adhesion assay. Figure 2 A and
B summarizes the effect of different concentrations of cyclic
peptides on BS-C-1 cell adhesion to fibronectin and laminin.
RGDDFV (Fig. 2A) exerted a potent inhibitory effect on BS-C-1
cell-matrix adhesion: the IC50 for adhesion to fibronectin and
laminin was 2 iM and 250 rM, respectively. RGDDFLG (Fig. 2B)
was less potent in inhibiting BS-C-1 cell adhesion to fibronectin
and laminin: the maximal concentration of peptide used in these
assays resulted in 58% inhibition of adhesion to fibronectin and
69% inhibition of adhesion to laminin. RDADFV, a cyclic peptide
which does not contain the RGD sequence, thus useful as control,
did not affect cell-matrix adhesion (for clarity only the effect of 25
.LM peptide is shown). Using PepTite 2000 as adhesion substrate,
RGDD FLG (25 .LM) did not affect BS-C-1 cell adhesion, whereas
an equimolar concentration of RGDDFV inhibited 90% adhesion
(data not shown). Based on profound differences in inhibitory
potency of these peptides, we utilized them for in vivo experiments
(see below) at the concentration (—4 fLM) which proved to be
effective for RGDDFV, but ineffective for RGDDFLG.
Effects of cyclic peptides in ischemic acute renal failure
The systemic effects of these cyclic peptides were examined in
vivo in rat model of ischemic acute renal failure. Figure 3
80
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summarizes the dynamics of Cr, BUN and creatinine clearance
(C) in the postischemic period. Cyclic RGDDFLG and
RGDDFV-treated groups showed a significantly lesser retention
of Cr, as well as an accelerated recovery of Ccr (P C 0.05) on
post-operative day 1, compared to both control groups (animals
treated with either the inactive cyclic peptide or with the vehicle).
In addition, a significant difference in Ccr between cyclic
RGDDFLG or RGDDFV-treated and cyclic RDADFV-treated
groups was observed on post-operative day 3. These data indicate
that the recovery of renal function after ischemic injury occurred
faster in cyclic RGDDFV-treated (2 days) or RGDDFLG-treated
(3 days) groups, compared to animals treated with either the
inactive peptide or with the vehicle (P C 0.05). The rank order for
the cyclic peptides in ameliorating ischemic acute renal failure
and accelerating recovery of Ccr was as follows: cyclic RGDDFV
 RGDDFLG RDADFV. The dynamics of BUN, although
displaying the trend similar to that of plasma creatinine, showed
no statistically significant differences between experimental
groups.
Microscopic examination of the urinary sediments revealed
striking differences between the experimental and control groups.
While control urine samples showed conglomerates of epithelial
cells on postischemic day 1, the urinary sediments of RGDDFLG-
or RGDDFV-treated animals displayed large numbers of dis-
persed cells (Fig. 4 A and B). The quantitation of desquamated
cells in control groups was not possible due to their agglomera-
tion.
The observed effects of cyclic RGD peptides were possibly
mediated by their tubular effects. Given the molecular weights of
these cyclic peptides being less than 900 Da, and their electrical
charge being close to neutral [15, 161, it is reasonable to assume
that the peptides should readily undergo glomerular filtration. To
prove that a systemically injected RGD peptide indeed appears in
the tubular lumen, where it could act on the desquamated cells,
we next examined urine sediments obtained from rats subjected to
renal ischemia and administered the biotinylated RGD peptide,
RGD[Bt-K5J, Urinary samples collected for three hours post-
operatively (N = 3) and stained with Rhodamine B streptavidin
revealed the presence of biotinylated ligand on the surface of fixed
non-permeabilized cells in the urine sediment (Fig. 4C). In
contrast, streptavidin staining of cells in the urine sediment from
rats that did not receive biotinylated RGD peptide was unstained
(data not shown). These data are consistent with the appearance
of RGD peptides in the tubular lumen, probably as a result of
their glomerular filtration.
The above observations provided direct evidence for the ame-
lioration of acute renal failure by a single systemic administration
of the cyclic RGD peptides and, quite unexpectedly, revealed no
profound in vivo differences between two peptides with vastly
different potencies in inhibiting in vitro cell-matrix adhesion. Such
an effect could be due to (1) the inhibition of the cell-cell rather
than cell-matrix adhesion, (2) a higher efficiency of peptides in
vivo than in vitro, or (3) to other unidentified factors. Since the
first possibility is readily testable, we next examined cell-cell
adhesion of BS-C-1 cells and the efficacy of cyclic RGD peptides
in its inhibition.
Effects of RGD peptides on cell-cell adhesion
To evaluate the propensity of dissociated BS-C-1 cells to
spontaneous aggregation, FACS analysis of the cells was per-
formed using the 90° side scatter and the fluorescence intensity of
a vital fluorophore, calcein, as indices of cellular conglomeration.
The orifice of a flow cytometer was kept wide open (200 tIm) to
allow for the passage of large cellular conglomerates. Intact
dispersed BS-C-1 cells studied at 0, 30 and 60 minutes after
dissociation showed a time-dependent increase in both the side
scatter and the fluorescence intensity (Fig. SA) consistent with the
possibility of spontaneous aggregation. This process was dramat-
ically enhanced when a matrix-like synthetic polypeptide, ProNec-
tin, was added at time 0 immediately after the acquisition of a
control scan (Fig. SB). The process of self-aggregation was
apparently inhibited by the addition of a linear RGD peptide (Fig.
SC). To gain more insight into the process of self-aggregation,
these experiments were modified to allow for cell counting under
light microscopy, as detailed in Methods. The number of unag-
gregated cells and cellular aggregates of various sizes were
quantitated at the commencement of experiments, and after 30
and 60 minutes. As shown in Figure 6, BS-C-1 cells exhibited the
strong tendency for self-conglomeration in suspension: the num-
ber of single cells progressively decreased with time in suspension,
while the number of conglomerated cells progressively increased.
When cell-cell adhesion assays were performed in the presence of
the cyclic RGD peptides at a concentration similar to that used in
vivo, the process of cellular aggregation was virtually abolished
(Fig. 6, compare with the effects of inactive peptide). Collectively,
these findings demonstrated that cyclic RGD peptides used in
these studies affected cell-matrix and cell-cell adhesion with
4
Fig. 7. Working hypothesis of the inhibitoty effects of RGD peptides on
cell-cell and cell-matrix adhesion resulting in amelioration of tubular obstruc-
tion in acute renal failure.
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different potencies; although differing in effectiveness in inhibiting
cell-matrix adhesion, both peptides were equipotent in the cell-
cell adhesion assay. Furthermore, these studies demonstrated that
a single systemic administration of cyclic peptides in vivo amelio-
rated acute ischemic renal failure, probably through their inhibi-
tory action on cell-cell conglomeration in the tubular lumen.
Discussion
Renal tubular obstruction plays an essential role in the main-
tenance of acute renal failure. We have previously demonstrated
that stressed BS-C-1 cells undergo desquamation due to the rapid
loss of focal adhesions. Using indirect immunocytochemistry of
the a3J31 integrin receptor as a convenient marker, its reorienta-
tion from the predominantly basolateral location in intact cells to
the apical membrane of stressed cells has been shown [71. These
findings suggested the possibility of inappropriate interactions
between the detached cells and the tubular lining via the apically
expressed integrins. Further in vitro analysis revealed that the
apically expressed integrins are functionally competent and that
they could be inhibited with linear RGD peptides. Micropuncture
studies of proximal tubular pressure in acute renal ischemia
showed that an RGD containing peptide effectively prevented its
elevation, a well established index of tubular obstruction. Based
on these observations, the RGD sequence was considered as a
potential therapeutic candidate for management of ischemic
acute renal failure. The present work not only explores this
possibility, but also establishes the high therapeutic potency of the
cyclic RGD peptides RGDDFLG and RGDDFV.
It is known that linear RGD peptides such as GRGDS and
GRGDNP are rapidly metabolized in vivo [17] and have a
relatively low affinity for integrins. Therefore, several strategies
such as polymerization or complexation with macromolecules
have been employed in the past to improve the biological prop-
erties of such peptides. However, these strategies invariably led to
the production of large molecules which a priori would not pass
the glomerular filtration barrier to reach the tubular lumen. An
alternative strategy of cyclization of RGD peptides has been
shown to result in a significant increase in their affinity and
inhibitory potency [18—20] without compromising the sieving
properties of the peptides. Indeed, our results from cell attach-
ment assay showed that cyclic RGDDFV and RGDDFLG peptides
inhibited BS-C-1 cell attachment to laminin and fibronectin at
concentrations as low as 25 .LM. Importantly, the former peptide
had a much higher in vitro potency for attenuating cell-matrix
adhesion than the latter one (see below).
In vivo studies were performed using these peptides at a
calculated systemic concentration approximately ten times lower
than the IC50 established by the in vitro laminin adhesion assay.
Even at this lower concentration, both cyclic RGD peptides
significantly reduced retention of Cr and accelerated Cr recovery
in the postischemic period. Hence, our observations establish for
the first time that cyclic peptides containing the RGD sequence
ameliorate ischemic acute renal failure. It is reasonable to suggest
that cyclic RGDDFLG and RGDDFV peptides were effective at
inhibiting tubular obstruction by predominantly preventing cell-
cell adhesion, rather than cell-matrix adhesion, as schematically
depicted in Figure 7. Such an inference is based on three
independent lines of experimental data. Firstly, the peptides were
used at concentrations which were only partially inhibitory for
cell-matrix adhesion in case of the cyclic RGDDFV and non-
inhibitory in case of the cyclic RGDDFLG. Secondly, comparison
of two cyclic RGD peptides with vastly different inhibitory poten-
cies in the cell-matrix adhesion assay showed that they were
equipotent in preventing cell-cell aggregation in vitro and almost
equipotent in ameliorating ischemic acute renal failure in vivo.
Thirdly, analysis of urine sediments from the cyclic RGDDFV-
and RGDDFLG-treated groups showed dispersed cells, in striking
contrast to the massive cellular conglomerates seen in the urine of
control animals.
Recently, several strategies to manipulate adhesion molecules
during the course of ischemic injury have been proposed. One
approach explores the therapeutic effects of anti-ICAM-1 and
anti-LFA-1 antibodies. It has been demonstrated that these
antibodies are effective in acute ischemic myocardial reperfusion
model [21]. More recent observations have provided data on the
therapeutic utility of these antibodies in protection against renal
ischemia [22]. Most probably these effects are confined to the
inhibition of leukocyte migration and/or blood coagulation in the
renal microvascular bed [23], thus resulting in improved hemody-
namics. In our experiments, thrombotic complications of the
prolonged clamping of the renal artery were negated by virtue of
anticoagulation with heparin performed prior to 45 minutes of
ischemia. The approach described in the present work utilizing
small, filterable and less immunogenic peptides is directed toward
inhibition of tubular obstruction, thus aiming to improve urody-
namics. Future attempts to combine both approaches may lead to
the potentiation of their effectiveness.
In conclusion, our studies demonstrate that cyclic RGD pep-
tides RGDDFLG and RGDDFV are highly potent inhibitors of
BS-C-1 cell-cell and cell-matrix adhesion and in vivo investigations
provide the first evidence of their utility in the amelioration of in
vivo ischemic acute renal failure.
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